On March 21, 2024, Amniotics AB (publ) (the "Company") disclosed a press
release with information on the Company's financial situation. On March 22, 2024, Magle Chemoswed Holding AB ("Magle Chemoswed")
The shareholders of Magle Chemoswed Holding AB , Org No. 556913-4710, are invited to the Annual General Meeting on Wednesday, April 26, 2023, at 10:00 CET at the Company’s premises at. | March 24, 2023
As from January 1, 2023, Magle Chemoswed Holding AB (publ) will change
Certified Adviser to Vator Securities AB. This information is distributed at the request of the Certified Adviser, Västra
hamnen
As from March 15, 2022, Magle Chemoswed Holding AB (publ) appoints Pareto
Securities AB as Liquidity Provider for its share in order to be compliant with
the rules of Nasdaq First North Growth Market.
Magle Chemoswed Holding AB Today Announced Financial Results for The First Quarter Of 2021
ACCESSWIRE
MALMÖ, SWEDEN / ACCESSWIRE / May 14, 2021 / Magle Chemoswed (STO:MAGLE) (FRA:52X)
The first quarter of 2021is in line with forecast and provides a strong performance basis for the remainder of 2021. High demand in the CDMO services area has followed the trend seen in the latter stages of 2020. The quarter was, as expected, a challenging start to the year and we have ended the first quarter strongly. We continue to deliver on our strategic priorities and remain focused on creating significant value for shareholders. We are making substantial progress in our development pipeline to expand our product portfolio on our technology platform. This is being supported with strong demand in the CDMO services area of the business. With the upcoming addition of PharmaCept in the next quarter, I am confident that we are well on our way to building an exciting foundation to bring our technol